IL-33 as a Novel Serum Prognostic Marker of Intracerebral Hemorrhage.

OBJECTIVE

Interleukin 33 (IL-33) is a key cytokine involved in inflammation and oxidative stress. The significance of serum IL-33 levels on the prognosis of patients with intracerebral hemorrhage (ICH) has not been well studied. The purpose of this study is to determine whether there is a relationship between the serum IL-33 level and the prognosis of patients with ICH upon admission.

METHODS

A total of 402 patients with confirmed ICH were included in this study. Their demographic data, medical history, laboratory data, imaging data, and clinical scores on admission were collected. At the same time, enzyme-linked immunoassay (ELISA) was used to detect the serum IL-33 levels of patients. The prognosis of patients was evaluated by mRS scale after 3 months, and mRS > 2 was defined as poor prognosis.

RESULTS

Among 402 patients with ICH, the number of patients with good prognosis and poor prognosis after 3 months was 148 and 254, respectively. Compared with the ICH group with poor prognosis, the ICH group with good prognosis had lower baseline NHISS scores ( = 0.039) and hematoma volume ( = 0.025) and higher GCS scores ( < 0.001) and serum IL-33 levels ( < 0.001). The results of linear correlation analysis showed that serum IL-33 levels were significantly negatively correlated with baseline NHISS scores ( = -0.224, = 0.033) and hematoma volume ( = -0.253, = 0.046) but were significantly positively correlated with baseline GCS scores ( = 0.296, = 0.020). The receiver operating characteristic curve (ROC) analysis showed that the sensitivity and specificity of serum IL-33 level in evaluating the prognosis of ICH were 72.1% and 74.3%, respectively. A cut-off value of serum IL-33 level < 109.3 pg/mL may indicate a poor prognosis for ICH.

CONCLUSIONS

Serum IL-33 level on admission may be a prognostic indicator of ICH, and its underlying mechanism needs further study.